Trial · NCT00085540
Adverse events58
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 58
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | anemia | Blood and lymphatic system disorders | Phase 1 Dose Escalation - Romidepsin | 3 | 8 | 3 |
| other | anemia | Blood and lymphatic system disorders | Phase 2 Dose From Phase 1 - Romidepsin | 8 | 40 | 8 |
| other | Leucopenia | Blood and lymphatic system disorders | Phase 1 Dose Escalation - Romidepsin | 3 | 8 | 3 |
| other | Leucopenia | Blood and lymphatic system disorders | Phase 2 Dose From Phase 1 - Romidepsin | 8 | 40 | 8 |
| other | neutropenia | Blood and lymphatic system disorders | Phase 1 Dose Escalation - Romidepsin | 3 | 8 | 3 |
| other | neutropenia | Blood and lymphatic system disorders | Phase 2 Dose From Phase 1 - Romidepsin | 7 | 40 | 7 |
| other | lymphopenia | Investigations | Phase 1 Dose Escalation - Romidepsin | 1 | 8 | 1 |
| other | lymphopenia | Investigations | Phase 2 Dose From Phase 1 - Romidepsin | 9 | 40 | 9 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Phase 1 Dose Escalation - Romidepsin | 6 | 8 | 6 |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Phase 2 Dose From Phase 1 - Romidepsin | 15 | 40 | 15 |
| other | Alkaline phosphatase elevation | Investigations | Phase 1 Dose Escalation - Romidepsin | 1 | 8 | 1 |
| other | Alkaline phosphatase elevation | Investigations | Phase 2 Dose From Phase 1 - Romidepsin | 1 | 40 | 1 |
| other | elevated ALT and/or AST | Investigations | Phase 1 Dose Escalation - Romidepsin | 2 | 8 | 2 |
| other | elevated ALT and/or AST | Investigations | Phase 2 Dose From Phase 1 - Romidepsin | 9 | 40 | 9 |
| other | anorexia | Metabolism and nutrition disorders | Phase 1 Dose Escalation - Romidepsin | 0 | 8 | 0 |
| other | anorexia | Metabolism and nutrition disorders | Phase 2 Dose From Phase 1 - Romidepsin | 4 | 40 | 4 |
| other | hyperglycemia | Metabolism and nutrition disorders | Phase 1 Dose Escalation - Romidepsin | 1 | 8 | 1 |
| other | hyperglycemia | Metabolism and nutrition disorders | Phase 2 Dose From Phase 1 - Romidepsin | 4 | 40 | 4 |
| other | hypocalcemia | Metabolism and nutrition disorders | Phase 1 Dose Escalation - Romidepsin | 2 | 8 | 2 |
| other | hypocalcemia | Metabolism and nutrition disorders | Phase 2 Dose From Phase 1 - Romidepsin | 2 | 40 | 2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00085540/events